Piraye Yurttas Beim

Dr. Beim has been innovating in women's health for over 20 years. During her Ph.D. work at Cornell (Weill, NYC) and Memorial Sloan Kettering Cancer Center in the early 2000s, she was on the front lines of precision medicine in oncology and saw the transformational impact of genomics on drug target selection and biomarker-based patient stratification on the emergence of targeted therapies and the corresponding improvement in the standard of care. After completing her post-doc focused on mammalian reproduction at the University of Cambridge (UK), she was inspired to found Celmatix. The vision of the company since its founding has been to accelerate precision medicine innovations in women’s health. Under Dr. Beim's leadership, Celmatix pioneered breakthroughs in decoding the genomic drivers of ovarian function and health and led the development of Celmatix’s ovarian health platform, an ambitious, decade-long, multi-omics initiative that has yielded unprecedented insight into the key molecular drivers of ovarian function and reproductive health conditions. Dr. Beim has also been a primary inventor of most of Celmatix’s innovations, including the lead AMHR2 agonist and follow-on AMHR2 antagonist programs, each a first-in-class approach to the modulation of ovarian folliculogenesis. In addition to leading the development of novel therapeutics, she has also developed diagnostics and digital health products in the women’s health field. Dr. Beim has also been widely recognized as a business leader. She is a member of the Aspen Global Leadership Network, was named to Crain’s 40 Under 40 as well as its Notable Women in Tech, Goldman Sachs's Most Intriguing Entrepreneurs, Top 15 founders disrupting their industries by Fortune, and Rock Health's Disruptive Founder of the Year.